REGN Today - Aug 06: Profit Slip Amid Trials
カートのアイテムが多すぎます
ご購入は五十タイトルがカートに入っている場合のみです。
カートに追加できませんでした。
しばらく経ってから再度お試しください。
ウィッシュリストに追加できませんでした。
しばらく経ってから再度お試しください。
ほしい物リストの削除に失敗しました。
しばらく経ってから再度お試しください。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
REGN Today - Aug 06: Profit Slip Amid Trials
-
ナレーター：
-
著者：
So, what went down? REGN started off kinda steady but ended up getting smoked a bit. It closed down after some mixed news about their earnings and clinical trials. You know how it goes—people get jittery, and when that happens, they hit the sell button fast.
Now, why did this happen? Well, there’s a lot swirling around Regeneron. First off, their earnings estimates are looking pretty good, hinting at some potential upside. But then you’ve got this nagging issue with their clinical trials, which reportedly led to a 9% drop earlier. Plus, there’s chatter about whether they’re prioritizing shareholder returns over the quality of earnings since profits seem to be slipping despite rising sales. It’s like a roller coaster over there—up one minute, down the next.
On top of that, Segall Bryant & Hamill just made a new investment in Regeneron, dropping over a million bucks into the company. That’s a pretty big vote of confidence, but it didn’t seem to lift the stock today. And Barclays is still keeping their buy rating on REGN, which is nice, but again, the market didn’t react positively.
One quick thing worth knowing: there’s a class action lawsuit related to securities fraud hanging over the company, and that’s probably adding to the nervous vibes among investors.
So, that’s the scoop on Regeneron today. It’s a bit of a mixed bag right now, but that’s how the stock game goes. Remember, this is just for your info and entertainment, not financial advice. Catch you later!
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません